195.017. Substances, how placed in schedules--list of scheduled substances--publication of schedules annually--electronic log of transactions to be maintained, when--certain products to be located beh

State Codes and Statutes

Statutes > Missouri > T12 > C195 > 195_017

Substances, how placed in schedules--list of scheduledsubstances--publication of schedules annually--electronic log oftransactions to be maintained, when--certain products to belocated behind pharmacy counter--exemption from requirements,when--rulemaking authority.

195.017. 1. The department of health and senior services shall place asubstance in Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States orlacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included inSchedule I;

(2) Any of the following opiates, including their isomers, esters,ethers, salts, and salts of isomers, esters, and ethers, unless specificallyexcepted, whenever the existence of these isomers, esters, ethers and salts ispossible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(d) Alphacetylmethadol;

(e) Alphameprodine;

(f) Alphamethadol;

(g) Alpha-methylfentanyl;

(h) Alpha-methylthiofentanyl;

(i) Benzethidine;

(j) Betacetylmethadol;

(k) Beta-hydroxyfentanyl;

(l) Beta-hydroxy-3-methylfentanyl;

(m) Betameprodine;

(n) Betamethadol;

(o) Betaprodine;

(p) Clonitazene;

(q) Dextromoramide;

(r) Diampromide;

(s) Diethylthiambutene;

(t) Difenoxin;

(u) Dimenoxadol;

(v) Dimepheptanol;

(w) Dimethylthiambutene;

(x) Dioxaphetyl butyrate;

(y) Dipipanone;

(z) Ethylmethylthiambutene;

(aa) Etonitazene;

(bb) Etoxeridine;

(cc) Furethidine;

(dd) Hydroxypethidine;

(ee) Ketobemidone;

(ff) Levomoramide;

(gg) Levophenacylmorphan;

(hh) 3-Methylfentanyl;

(ii) 3-Methylthiofentanyl;

(jj) Morpheridine;

(kk) MPPP;

(ll) Noracymethadol;

(mm) Norlevorphanol;

(nn) Normethadone;

(oo) Norpipanone;

(pp) Para-fluorofentanyl;

(qq) PEPAP;

(rr) Phenadoxone;

(ss) Phenampromide;

(tt) Phenomorphan;

(uu) Phenoperidine;

(vv) Piritramide;

(ww) Proheptazine;

(xx) Properidine;

(yy) Propiram;

(zz) Racemoramide;

(aaa) Thiofentanyl;

(bbb) Tilidine;

(ccc) Trimeperidine;

(3) Any of the following opium derivatives, their salts, isomers andsalts of isomers unless specifically excepted, whenever the existence of thesesalts, isomers and salts of isomers is possible within the specific chemicaldesignation:

(a) Acetorphine;

(b) Acetyldihydrocodeine;

(d) Codeine methylbromide;

(e) Codeine-N-Oxide;

(f) Cyprenorphine;

(g) Desomorphine;

(h) Dihydromorphine;

(i) Drotebanol;

(j) Etorphine (except hydrochloride salt);

(k) Heroin;

(l) Hydromorphinol;

(m) Methyldesorphine;

(n) Methyldihydromorphine;

(o) Morphine methylbromide;

(p) Morphine methylsulfonate;

(q) Morphine-N-Oxide;

(r) Myrophine;

(s) Nicocodeine;

(t) Nicomorphine;

(u) Normorphine;

(v) Pholcodine;

(w) Thebacon;

(4) Any material, compound, mixture or preparation which contains anyquantity of the following hallucinogenic substances, their salts, isomers andsalts of isomers, unless specifically excepted, whenever the existence ofthese salts, isomers, and salts of isomers is possible within the specificchemical designation:

(a) 4-bromo-2, 5-dimethoxyamphetamine;

(b) 4-bromo-2, 5-dimethoxyphenethylamine;

(d) 2,5-dimethoxy-4-ethylamphetamine;

(e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;

(f) 4-methoxyamphetamine;

(g) 5-methoxy-3,4-methylenedioxyamphetamine;

(h) 4-methyl-2, 5-dimethoxyamphetamine;

(i) 3,4-methylenedioxyamphetamine;

(j) 3,4-methylenedioxymethamphetamine;

(k) 3,4-methylenedioxy-N-ethylamphetamine;

(l) *N-hydroxy-3, 4-methylenedioxyamphetamine;

(m) 3,4,5-trimethoxyamphetamine;

(n) Alpha-ethyltryptamine;

(o) Alpha-methyltryptamine;

(p) Bufotenine;

(q) Diethyltryptamine;

(r) Dimethyltryptamine;

(s) 5-methoxy-N,N-diisopropyltryptamine;

(t) Ibogaine;

(u) Lysergic acid diethylamide;

(v) Marijuana or marihuana;

(w) Mescaline;

(x) Parahexyl;

(y) Peyote, to include all parts of the plant presently classifiedbotanically as Lophophora Williamsil Lemaire, whether growing or not; theseeds thereof; any extract from any part of such plant; and every compound,manufacture, salt, derivative, mixture or preparation of the plant, its seedor extracts;

(z) N-ethyl-3-piperidyl benzilate;

(aa) N-methyl-3-piperidyl benzilate;

(bb) Psilocybin;

(cc) Psilocyn;

(dd) Tetrahydrocannabinols naturally contained in a plant of the genusCannabis (cannabis plant), as well as synthetic equivalents of the substancescontained in the cannabis plant, or in the resinous extractives of such plant,or synthetic substances, derivatives, and their isomers with similar chemicalstructure and pharmacological activity to those substances contained in theplant, such as the following:

a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;

b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;

c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;

d. Any compounds of these structures, regardless of numericaldesignation of atomic positions covered;

(ee) Ethylamine analog of phencyclidine;

(ff) Pyrrolidine analog of phencyclidine;

(gg) Thiophene analog of phencyclidine;

(hh) 1-â1-(2-thienyl)cyclohexylãpyrrolidine;

(ii) Salvia divinorum;

(jj) Salvinorin A;

(5) Any material, compound, mixture or preparation containing anyquantity of the following substances having a depressant effect on the centralnervous system, including their salts, isomers and salts of isomers wheneverthe existence of these salts, isomers and salts of isomers is possible withinthe specific chemical designation:

(a) Gamma-hydroxybutyric acid;

(b) Mecloqualone;

(6) Any material, compound, mixture or preparation containing anyquantity of the following substances having a stimulant effect on the centralnervous system, including their salts, isomers and salts of isomers:

(a) Aminorex;

(b) N-benzylpiperazine;

(d) Fenethylline;

(e) Methcathinone;

(f) (+,-)cis-4-methylaminorex((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);

(g) N-ethylamphetamine;

(h) N,N-dimethylamphetamine;

(7) A temporary listing of substances subject to emergency schedulingunder federal law shall include any material, compound, mixture or preparationwhich contains any quantity of the following substances:

(a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), itsoptical isomers, salts and salts of isomers;

(b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide(thenylfentanyl), its optical isomers, salts and salts of isomers;

(8) Khat, to include all parts of the plant presently classifiedbotanically as catha edulis, whether growing or not; the seeds thereof; anyextract from any part of such plant; and every compound, manufacture, salt,derivative, mixture, or preparation of the plant, its seed or extracts.

3. The department of health and senior services shall place a substancein Schedule II if it finds that:

(1) The substance has high potential for abuse;

(2) The substance has currently accepted medical use in treatment in theUnited States, or currently accepted medical use with severe restrictions; and

(3) The abuse of the substance may lead to severe psychic or physicaldependence.

4. The controlled substances listed in this subsection are included inSchedule II:

(1) Any of the following substances whether produced directly orindirectly by extraction from substances of vegetable origin, or independentlyby means of chemical synthesis, or by combination of extraction and chemicalsynthesis:

(a) Opium and opiate and any salt, compound, derivative or preparationof opium or opiate, excluding apomorphine, thebaine-derived butorphanol,dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone, and theirrespective salts but including the following:

a. Raw opium;

b. Opium extracts;

c. Opium fluid;

d. Powdered opium;

e. Granulated opium;

f. Tincture of opium;

g. Codeine;

h. Ethylmorphine;

i. Etorphine hydrochloride;

j. Hydrocodone;

k. Hydromorphone;

l. Metopon;

m. Morphine;

n. Oxycodone;

o. Oxymorphone;

p. Thebaine;

(b) Any salt, compound, derivative, or preparation thereof which ischemically equivalent or identical with any of the substances referred to inthis subdivision, but not including the isoquinoline alkaloids of opium;

(d) Coca leaves and any salt, compound, derivative, or preparation ofcoca leaves, and any salt, compound, derivative, or preparation thereof whichis chemically equivalent or identical with any of these substances, but notincluding decocainized coca leaves or extractions which do not contain cocaineor ecgonine;

(e) Concentrate of poppy straw (the crude extract of poppy straw ineither liquid, solid or powder form which contains the phenanthrene alkaloidsof the opium poppy);

(2) Any of the following opiates, including their isomers, esters,ethers, salts, and salts of isomers, whenever the existence of these isomers,esters, ethers and salts is possible within the specific chemical designation,dextrorphan and levopropoxyphene excepted:

(a) Alfentanil;

(b) Alphaprodine;

(d) Bezitramide;

(e) Bulk dextropropoxyphene;

(f) Carfentanil;

(g) Butyl nitrite;

(h) Dihydrocodeine;

(i) Diphenoxylate;

(j) Fentanyl;

(k) Isomethadone;

(l) Levo-alphacetylmethadol;

(m) Levomethorphan;

(n) Levorphanol;

(o) Metazocine;

(p) Methadone;

(q) Meperidine;

(r) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;

(s) Moramide-Intermediate, 2-methyl-3-morpholino-1,1-diphenylpropane--carboxylic acid;

(t) Pethidine (meperidine);

(u) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;

(v) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;

(w) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperdine-4-carboxylicacid;

(x) Phenazocine;

(y) Piminodine;

(z) Racemethorphan;

(aa) Racemorphan;

(bb) Remifentanil;

(cc) Sufentanil;

(3) Any material, compound, mixture, or preparation which contains anyquantity of the following substances having a stimulant effect on the centralnervous system:

(a) Amphetamine, its salts, optical isomers, and salts of its opticalisomers;

(b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;

(d) Phenmetrazine and its salts;

(e) Methylphenidate;

(4) Any material, compound, mixture, or preparation which contains anyquantity of the following substances having a depressant effect on the centralnervous system, including its salts, isomers, and salts of isomers wheneverthe existence of those salts, isomers, and salts of isomers is possible withinthe specific chemical designation:

(a) Amobarbital;

(b) Glutethimide;

(d) Phencyclidine;

(e) Secobarbital;

(5) Any material or compound which contains any quantity of nabilone;

(6) Any material, compound, mixture, or preparation which contains anyquantity of the following substances:

(a) Immediate precursor to amphetamine and methamphetamine:Phenylacetone;

(b) Immediate precursors to phencyclidine (PCP):

a. 1-phenylcyclohexylamine;

b. 1-piperidinocyclohexanecarbonitrile (PCC).

5. The department of health and senior services shall place a substancein Schedule III if it finds that:

(1) The substance has a potential for abuse less than the substanceslisted in Schedules I and II;

(2) The substance has currently accepted medical use in treatment in theUnited States; and

(3) Abuse of the substance may lead to moderate or low physicaldependence or high psychological dependence.

6. The controlled substances listed in this subsection are included inSchedule III:

(1) Any material, compound, mixture, or preparation which contains anyquantity of the following substances having a potential for abuse associatedwith a stimulant effect on the central nervous system:

(a) Benzphetamine;

(b) Chlorphentermine;

(d) Phendimetrazine;

(2) Any material, compound, mixture or preparation which contains anyquantity or salt of the following substances or salts having a depressanteffect on the central nervous system:

(a) Any material, compound, mixture or preparation which contains anyquantity or salt of the following substances combined with one or more activemedicinal ingredients:

a. Amobarbital;

b. Secobarbital;

c. Pentobarbital;

(b) Any suppository dosage form containing any quantity or salt of thefollowing:

a. Amobarbital;

b. Secobarbital;

c. Pentobarbital;

(d) Chlorhexadol;

(e) Embutramide;

(f) Gamma hydroxybutyric acid and its salts, isomers, and salts ofisomers contained in a drug product for which an application has been approvedunder Section 505 of the federal Food, Drug, and Cosmetic Act;

(g) Ketamine, its salts, isomers, and salts of isomers;

(h) Lysergic acid;

(i) Lysergic acid amide;

(j) Methyprylon;

(k) Sulfondiethylmethane;

(l) Sulfonethylmethane;

(m) Sulfonmethane;

(n) Tiletamine and zolazepam or any salt thereof;

(3) Nalorphine;

(4) Any material, compound, mixture, or preparation containing limitedquantities of any of the following narcotic drugs or their salts:

(a) Not more than 1.8 grams of codeine per one hundred milliliters ornot more than ninety milligrams per dosage unit, with an equal or greaterquantity of an isoquinoline alkaloid of opium;

(b) Not more than 1.8 grams of codeine per one hundred milliliters ornot more than ninety milligrams per dosage unit with one or more active,nonnarcotic ingredients in recognized therapeutic amounts;

(c) Not more than three hundred milligrams of hydrocodone per onehundred milliliters or not more than fifteen milligrams per dosage unit, witha fourfold or greater quantity of an isoquinoline alkaloid of opium;

(d) Not more than three hundred milligrams of hydrocodone per onehundred milliliters or not more than fifteen milligrams per dosage unit, withone or more active nonnarcotic ingredients in recognized therapeutic amounts;

(e) Not more than 1.8 grams of dihydrocodeine per one hundredmilliliters or not more than ninety milligrams per dosage unit, with one ormore active nonnarcotic ingredients in recognized therapeutic amounts;

(f) Not more than three hundred milligrams of ethylmorphine per onehundred milliliters or not more than fifteen milligrams per dosage unit, withone or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(g) Not more than five hundred milligrams of opium per one hundredmilliliters or per one hundred grams or not more than twenty-five milligramsper dosage unit, with one or more active nonnarcotic ingredients in recognizedtherapeutic amounts;

(h) Not more than fifty milligrams of morphine per one hundredmilliliters or per one hundred grams, with one or more active, nonnarcoticingredients in recognized therapeutic amounts;

(5) Any material, compound, mixture, or preparation containing any ofthe following narcotic drugs or their salts, as set forth in subdivision (6)of this subsection; buprenorphine;

(6) Anabolic steroids. Any drug or hormonal substance, chemically andpharmacologically related to testosterone (other than estrogens, progestins,corticosteroids, and dehydroepiandrosterone) that promotes muscle growth,except an anabolic steroid which is expressly intended for administrationthrough implants to cattle or other nonhuman species and which has beenapproved by the Secretary of Health and Human Services for thatadministration. If any person prescribes, dispenses, or distributes suchsteroid for human use, such person shall be considered to have prescribed,dispensed, or distributed an anabolic steroid within the meaning of thisparagraph. Unless specifically excepted or unless listed in another schedule,any material, compound, mixture or preparation containing any quantity of thefollowing substances, including its salts, esters and ethers:

(a) 3{,17-dihydroxy-5a-androstane;

(b) 3@,17{-dihydroxy-5a-androstane;

(d) 1-androstenediol (3{,17{-dihydroxy-5@-androst-1-ene);

(e) 1-androstenediol (3@,17{-dihydroxy-5@-androst-1-ene);

(f) 4-androstenediol (3{,17{-dihydroxy-androst-4-ene);

(g) 5-androstenediol (3{,17{-dihydroxy-androst-5-ene);

(h) 1-androstenedione (â5@ã-androst-1-en-3,17-dione);

(i) 4-androstenedione (androst-4-en-3,17-dione);

(j) 5-androstenedione (androst-5-en-3,17-dione);

(k) Bolasterone (7@, 17@-dimethyl-17{-hydroxyandrost-4-en-3-one);

(l) Boldenone (17{-hydroxyandrost-1,4,-diene-3-one);

(m) Calusterone (7{, 17@-dimethyl-17{-hydroxyandrost-4-en-3-one);

(n) Clostebol (4-chloro-17{-hydroxyandrost-4-en-3-one);

(o) Dehydrochloromethyltestosterone(4-chloro-17{-hydroxy-17@-methyl-androst-1,4-dien-3-one);

(p) }1-dihydrotestosterone (a.k.a.'1-testosterone')(17{-hydroxy-5@-androst-1-en-3-one);

(q) 4-dihydrotestosterone (17{-hydroxy-androstan-3-one);

(r) Drostanolone (17{-hydroxy-2@-methyl-5@-androstan-3-one);

(s) Ethylestrenol (17@-ethyl-17{-hydroxyestr-4-ene);

(t) Fluoxymesterone(9-fluoro-17@-methyl-11{,17{-dihydroxyandrost-4-en-3-one);

(u) Formebolone(2-formyl-17@-methyl-11@,17{-dihydroxyandrost-1,4-dien-3-one);

(v) Furazabol (17@-methyl-17{-hydroxyandrostanoâ2,3-cã-furazan);

(w) 13{-ethyl-17{-hydroxygon-4-en-3-one;

(x) 4-hydroxytestosterone (4,17{-dihydroxy-androst-4-en-3-one);

(y) 4-hydroxy-19-nortestosterone (4,17{-dihydroxy-estr-4-en-3-one);

(z) Mestanolone (17@-methyl-17{-hydroxy-5-androstan-3-one);

(aa) Mesterolone (1@methyl-17{-hydroxy-â5@ã-androstan-3-one);

(bb) Methandienone (17@-methyl-17{-hydroxyandrost-1,4-dien-3-one);

(cc) Methandriol (17@-methyl-3{,17{-dihydroxyandrost-5-ene);

(dd) Methenolone (1-methyl-17{-hydroxy-5@-androst-1-en-3-one);

(ee) 17@-methyl-3{,17{-dihydroxy-5a-androstane);

(ff) 17@-methyl-3@,17{-dihydroxy-5a-androstane);

(gg) 17@-methyl-3{,17{-dihydroxyandrost-4-ene;

(hh) 17@-methyl-4-hydroxynandrolone(17@-methyl-4-hydroxy-17{-hydroxyestr-4-en-3-one);

(ii) Methyldienolone (17@-methyl-17{-hydroxyestra-4,9(10)-dien-3-one);

(jj) Methyltrienolone (17@-methyl-17{-hydroxyestra-4,9-11-trien-3-one);

(kk) Methyltestosterone (17@-methyl-17{-hydroxyandrost-4-en-3-one);

(ll) Mibolerone (7@,17@-dimethyl-17{-hydroxyestr-4-en-3-one);

(mm) 17@-methyl-}1-dihydrotestosterone(17b{-hydroxy-17@-methyl-5@-androst-1-en-3-one) (a.k.a.'17-@-methyl-1-testosterone');

(nn) Nandrolone (17{-hydroxyestr-4-ene-3-one);

(oo) 19-nor-4-androstenediol (3{,17{-dihydroxyestr-4-ene);

(pp) 19-nor-4-androstenediol (3@,17{-dihydroxyestr-4-ene);

(qq) 19-nor-5-androstenediol (3{,17{-dihydroxyestr-5-ene);

(rr) 19-nor-5-androstenediol (3@,17{-dihydroxyestr-5-ene);

(ss) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

(tt) 19-nor-5-androstenedione (estr-5-en-3,17-dione);

(uu) Norbolethone (13{,17@-diethyl-17{-hydroxygon-4-en-3-one);

(vv) Norclostebol (4-chloro-17{-hydroxyestr-4-en-3-one);

(ww) Norethandrolone (17@-ethyl-17{-hydroxyestr-4-en-3-one);

(xx) Normethandrolone (17@-methyl-17{-hydroxyestr-4-en-3-one);

(yy) Oxandrolone (17@-methyl-17{-hydroxy-2-oxa-â5@ã-androstan-3-one);

(zz) Oxymesterone (17@-methyl-4,17{-dihydroxyandrost-4-en-3-one);

(aaa) Oxymethalone(17a-methyl-2-hydroxymethylene-17{-hydroxy-â5@ã-androstan-3-one);

(bbb) Stanozolol(17@-methyl-17{-hydroxy-â5@ã-androst-2-enoâ3,2-cã-pyrazole);

(ccc) Stenbolone (17{-hydroxy-2-methyl-â5@ã-androst-1-en-3-one);

(ddd) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oicacid lactone);

(eee) Testosterone (17{-hydroxyandrost-4-en-3-one);

(fff) Tetrahydrogestrinone(13{,17@-diethyl-17{-hydroxygon-4,9,11-trien-3-one);

(ggg) Trenbolone (17{-hydroxyestr-4,9,11-trien-3-one);

(hhh) Any salt, ester, or ether of a drug or substance described orlisted in this subdivision, except an anabolic steroid which is expresslyintended for administration through implants to cattle or other nonhumanspecies and which has been approved by the Secretary of Health and HumanServices for that administration;

(7) Dronabinol (synthetic) in sesame oil and encapsulated in a softgelatin capsule in a United States Food and Drug Administration approved drugproduct;

(8) The department of health and senior services may except by rule anycompound, mixture, or preparation containing any stimulant or depressantsubstance listed in subdivisions (1) and (2) of this subsection from theapplication of all or any part of sections 195.010 to 195.320 if the compound,mixture, or preparation contains one or more active medicinal ingredients nothaving a stimulant or depressant effect on the central nervous system, and ifthe admixtures are included therein in combinations, quantity, proportion, orconcentration that vitiate the potential for abuse of the substances whichhave a stimulant or depressant effect on the central nervous system.

7. The department of health and senior services shall place a substancein Schedule IV if it finds that:

(1) The substance has a low potential for abuse relative to substancesin Schedule III;

(2) The substance has currently accepted medical use in treatment in theUnited States; and

(3) Abuse of the substance may lead to limited physical dependence orpsychological dependence relative to the substances in Schedule III.

8. The controlled substances listed in this subsection are included inSchedule IV:

(1) Any material, compound, mixture, or preparation containing any ofthe following narcotic drugs or their salts calculated as the free anhydrousbase or alkaloid, in limited quantities as set forth below:

(a) Not more than one milligram of difenoxin and not less thantwenty-five micrograms of atropine sulfate per dosage unit;

(b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane);

(c) Any of the following limited quantities of narcotic drugs or theirsalts, which shall include one or more nonnarcotic active medicinalingredients in sufficient proportion to confer upon the compound, mixture orpreparation valuable medicinal qualities other than those possessed by thenarcotic drug alone:

a. Not more than two hundred milligrams of codeine per one hundredmilliliters or per one hundred grams;

b. Not more than one hundred milligrams of dihydrocodeine per onehundred milliliters or per one hundred grams;

c. Not more than one hundred milligrams of ethylmorphine per one hundredmilliliters or per one hundred grams;

(2) Any material, compound, mixture or preparation containing anyquantity of the following substances, including their salts, isomers, andsalts of isomers whenever the existence of those salts, isomers, and salts ofisomers is possible within the specific chemical designation:

(a) Alprazolam;

(b) Barbital;

(d) Camazepam;

(e) Chloral betaine;

(f) Chloral hydrate;

(g) Chlordiazepoxide;

(h) Clobazam;

(i) Clonazepam;

(j) Clorazepate;

(k) Clotiazepam;

(l) Cloxazolam;

(m) Delorazepam;

(n) Diazepam;

(o) Dichloralphenazone;

(p) Estazolam;

(q) Ethchlorvynol;

(r) Ethinamate;

(s) Ethyl loflazepate;

(t) Fludiazepam;

(u) Flunitrazepam;

(v) Flurazepam;

(w) Halazepam;

(x) Haloxazolam;

(y) Ketazolam;

(z) Loprazolam;

(aa) Lorazepam;

(bb) Lormetazepam;

(cc) Mebutamate;

(dd) Medazepam;

(ee) Meprobamate;

(ff) Methohexital;

(gg) Methylphenobarbital (mephobarbital);

(hh) Midazolam;

(ii) Nimetazepam;

(jj) Nitrazepam;

(kk) Nordiazepam;

(ll) Oxazepam;

(mm) Oxazolam;

(nn) Paraldehyde;

(oo) Petrichloral;

(pp) Phenobarbital;

(qq) Pinazepam;

(rr) Prazepam;

(ss) Quazepam;

(tt) Temazepam;

(uu) Tetrazepam;

(vv) Triazolam;

(ww) Zaleplon;

(xx) Zolpidem;

(yy) Zopiclone;

(3) Any material, compound, mixture, or preparation which contains anyquantity of the following substance including its salts, isomers and salts ofisomers whenever the existence of such salts, isomers and salts of isomers ispossible: fenfluramine;

(4) Any material, compound, mixture or preparation containing anyquantity of the following substances having a stimulant effect on the centralnervous system, including their salts, isomers and salts of isomers:

(a) Cathine ((+)-norpseudoephedrine);

(b) Diethylpropion;

(d) Fenproporex;

(e) Mazindol;

(f) Mefenorex;

(g) Modafinil;

(h) Pemoline, including organometallic complexes and chelates thereof;

(i) Phentermine;

(j) Pipradrol;

(k) Sibutramine;

(l) SPA ((-)-1-dimethyamino-1,2-diphenylethane);

(5) Any material, compound, mixture or preparation containing anyquantity of the following substance, including its salts:

(a) butorphanol;

(b) pentazocine;

(6) Ephedrine, its salts, optical isomers and salts of optical isomers,when the substance is the only active medicinal ingredient;

(7) The department of health and senior services may except by rule anycompound, mixture, or preparation containing any depressant substance listedin subdivision (1) of this subsection from the application of all or any partof sections 195.010 to 195.320 if the compound, mixture, or preparationcontains one or more active medicinal ingredients not having a depressanteffect on the central nervous system, and if the admixtures are includedtherein in combinations, quantity, proportion, or concentration that vitiatethe potential for abuse of the substances which have a depressant effect onthe central nervous system.

9. The department of health and senior services shall place a substancein Schedule V if it finds that:

(1) The substance has low potential for abuse relative to the controlledsubstances listed in Schedule IV;

(2) The substance has currently accepted medical use in treatment in theUnited States; and

(3) The substance has limited physical dependence or psychologicaldependence liability relative to the controlled substances listed in ScheduleIV.

10. The controlled substances listed in this subsection are included inSchedule V:

(1) Any compound, mixture or preparation containing any of the followingnarcotic drugs or their salts calculated as the free anhydrous base oralkaloid, in limited quantities as set forth below, which also contains one ormore nonnarcotic active medicinal ingredients in sufficient proportion toconfer upon the compound, mixture or preparation valuable medicinal qualitiesother than those possessed by the narcotic drug alone:

(a) Not more than two and five-tenths milligrams of diphenoxylate andnot less than twenty-five micrograms of atropine sulfate per dosage unit;

(b) Not more than one hundred milligrams of opium per one hundredmilliliters or per one hundred grams;

(c) Not more than five-tenths milligram of difenoxin and not less thantwenty-five micrograms of atropine sulfate per dosage unit;

(2) Any material, compound, mixture or preparation which contains anyquantity of the following substance having a stimulant effect on the centralnervous system including its salts, isomers and salts of isomers:pyrovalerone;

(3) Any compound, mixture, or preparation containing any detectablequantity of pseudoephedrine or its salts or optical isomers, or salts ofoptical isomers or any compound, mixture, or preparation containing anydetectable quantity of ephedrine or its salts or optical isomers, or salts ofoptical isomers;

(4) Unless specifically exempted or excluded or unless listed in anotherschedule, any material, compound, mixture, or preparation which contains anyquantity of the following substances having a depressant effect on the centralnervous system, including its salts: pregabalinâ(S)-3-(aminomethyl)-5-methylhexanoic acidã.

11. If any compound, mixture, or preparation as specified in subdivision(3) of subsection 10 of this section is dispensed, sold, or distributed in apharmacy without a prescription:

(1) All packages of any compound, mixture, or preparation containing anydetectable quantity of pseudoephedrine, its salts or optical isomers, or saltsof optical isomers or ephedrine, its salts or optical isomers, or salts ofoptical isomers, shall be offered for sale only from behind a pharmacy counterwhere the public is not permitted, and only by a registered pharmacist orregistered pharmacy technician; and

(2) Any person purchasing, receiving or otherwise acquiring anycompound, mixture, or preparation containing any detectable quantity ofpseudoephedrine, its salts or optical isomers, or salts of optical isomers orephedrine, its salts or optical isomers, or salts of optical isomers shall beat least eighteen years of age; and

(3) The pharmacist, intern pharmacist, or registered pharmacy technicianshall require any person, prior to their purchasing, receiving or otherwiseacquiring such compound, mixture, or preparation to furnish suitable photoidentification that is issued by a state or the federal government or adocument that, with respect to identification, is considered acceptable andshowing the date of birth of the person;

(4) The seller shall deliver the product directly into the custody ofthe purchaser.

12. Pharmacists, intern pharmacists, and registered pharmacy techniciansshall implement and maintain an electronic log of each transaction. Such logshall include the following information:

(1) The name, address, and signature of the purchaser;

(2) The amount of the compound, mixture, or preparation purchased;

(3) The date and time of each purchase; and

(4) The name or initials of the pharmacist, intern pharmacist, orregistered pharmacy technician who dispensed the compound, mixture, orpreparation to the purchaser.

13. Each pharmacy shall submit information regarding sales of anycompound, mixture, or preparation as specified in subdivision (3) ofsubsection 10 of this section in accordance with transmission methods andfrequency established by the department by regulation;

14. No person shall dispense, sell, purchase, receive, or otherwiseacquire quantities greater than those specified in this chapter.

15. All persons who dispense or offer for sale pseudoephedrine andephedrine products in a pharmacy shall ensure that all such products arelocated only behind a pharmacy counter where the public is not permitted.

16. Any person who knowingly or recklessly violates the provisions ofsubsections 11 to 15 of this section is guilty of a class A misdemeanor.

17. The scheduling of substances specified in subdivision (3) ofsubsection 10 of this section and subsections 11, 12, 14, and 15 of thissection shall not apply to any compounds, mixtures, or preparations that arein liquid or liquid-filled gel capsule form or to any compound, mixture, orpreparation specified in subdivision (3) of subsection 10 of this sectionwhich must be dispensed, sold, or distributed in a pharmacy pursuant to aprescription.

18. The manufacturer of a drug product or another interested party mayapply with the department of health and senior services for an exemption fromthis section. The department of health and senior services may grant anexemption by rule from this section if the department finds the drug productis not used in the illegal manufacture of methamphetamine or other controlledor dangerous substances. The department of health and senior services shallrely on reports from law enforcement and law enforcement evidentiarylaboratories in determining if the proposed product can be used to manufactureillicit controlled substances.

19. The department of health and senior services shall revise andrepublish the schedules annually.

20. The department of health and senior services shall promulgate rulesunder chapter 536, RSMo, regarding the security and storage of Schedule Vcontrolled substances, as described in subdivision (3) of subsection 10 ofthis section, for distributors as registered by the department of health andsenior services.

21. Logs of transactions required to be kept and maintained by thissection and section 195.417 shall create a rebuttable presumption that theperson whose name appears in the logs is the person whose transactions arerecorded in the logs.

(L. 1971 H.B. 69, A.L. 1987 H.B. 51 & 49, A.L. 1989 S.B. 215 & 58, A.L. 1994 S.B. 594, A.L. 1996 H.B. 1301 & 1298, A.L. 1997 H.B. 635, A.L. 1998 H.B. 1357, A.L. 2001 H.B. 471, A.L. 2005 H.B. 353 merged with H.B. 441 merged with S.B. 10 & 27, A.L. 2006 S.B. 756, A.L. 2008 S.B. 724)
Effective 1-01-09
*"N-" does not appear in original rolls, a typographical error.

State Codes and Statutes

State Codes and Statutes

State Codes and Statutes

State Codes and Statutes

Loading..

Loading, Please Wait!